Rayner Intraocular Lenses Ltd. Received approval from the FDA in December 2011 to market the C-flex Aspheric 970C IOL in the United States.
London-Rayner Intraocular Lenses Ltd. Received approval from the FDA last month to market the C-flex aspheric 970C IOL in the United States.
Now, surgeons who have enjoyed the material, design, and performance benefits of the spherical monofocal hydrophilic acrylic, single-piece C-flex 570C IOL (Rayner Intraocular Lenses) have the opportunity to take advantage of these features combined with those of aspheric optics. The C-flex 970C IOL will be available in a power range from +18 to +30 D in 0.5-D steps.
"It is the platform that determines the stability of the IOL in the eye, and with the 'flex' family of IOL implants with different optics from Rayner, European surgeons are spoiled for choice," Dr. Claoué said. "With these products, we can offer patients state-of-the-art implant technology while customizing the optic to meet the individual's needs."
In addition to its spherical aberration-neutral optic, the C-flex 970C IOL features Rayner's unique hydrophilic acrylic material (Rayacryl) and anti-vaulting haptic (AVH) technology, along with an enhanced Amon-Apple square edge, and it is delivered with an ergonomic, singleuse, soft-tipped injector system.
"Current evidence shows a significant number of patients experience degradation of vision when [an IOL with a negative spherical aberration is implanted]," he said. "Furthermore, some residual spherical aberration can provide better depth of field.
"Overall, there is a good body of literature in peer-reviewed journals showing that [IOLs with] zero spherical aberration perform better under almost all circumstances compared with [lenses with] negative spherical aberration, and when patients have been able to discern a difference, they generally prefer a [lens with] zero spherical aberration," he added.